Trevena Inc (NASDAQ:TRVN) – Analysts at Oppenheimer raised their FY2018 earnings estimates for Trevena in a research report issued on Monday, March 12th, according to Zacks Investment Research. Oppenheimer analyst D. Archila now anticipates that the biopharmaceutical company will post earnings per share of ($0.79) for the year, up from their previous estimate of ($0.82). Oppenheimer currently has a “Buy” rating on the stock. Oppenheimer also issued estimates for Trevena’s Q4 2018 earnings at ($0.23) EPS.
Trevena (NASDAQ:TRVN) last announced its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.02.
Several other research analysts have also weighed in on TRVN. Zacks Investment Research lowered Trevena from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research report on Saturday, January 20th. HC Wainwright lifted their price objective on Trevena to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. Trevena presently has a consensus rating of “Buy” and a consensus target price of $7.06.
TRVN traded down $0.03 during midday trading on Thursday, hitting $1.63. 825,168 shares of the company were exchanged, compared to its average volume of 673,098. Trevena has a 1-year low of $1.34 and a 1-year high of $3.64. The company has a current ratio of 3.71, a quick ratio of 3.71 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $111.14, a PE ratio of -1.35 and a beta of -0.52.
Several hedge funds have recently bought and sold shares of TRVN. Alliancebernstein L.P. raised its position in shares of Trevena by 51.9% in the 2nd quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 18,900 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Trevena by 26.4% in the 2nd quarter. Teachers Advisors LLC now owns 98,153 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 20,482 shares in the last quarter. TIAA CREF Investment Management LLC increased its position in Trevena by 8.3% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 237,045 shares of the biopharmaceutical company’s stock valued at $545,000 after buying an additional 18,190 shares in the last quarter. Nationwide Fund Advisors increased its position in Trevena by 92.1% in the 2nd quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 23,557 shares in the last quarter. Finally, Northern Trust Corp increased its position in Trevena by 15.8% in the 2nd quarter. Northern Trust Corp now owns 572,662 shares of the biopharmaceutical company’s stock valued at $1,318,000 after buying an additional 77,934 shares in the last quarter. 50.47% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/fy2018-eps-estimates-for-trevena-inc-increased-by-analyst-trvn.html.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Get a free copy of the Zacks research report on Trevena (TRVN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.